67 results
To evaluate the effect of AMG 334 compared to placebo on the change from baseline in mean monthly migraine days, in subjects with episodic migraine.hypothesis: In subjects with episodic migraine, AMG 334 has a greater reduction from baseline in mean…
We investigated the safety and efficacy of on-demand SPG stimulation for chronic CH (CCH).
To determine the mechanism of action of propranolol in the prophylactic treatment of migraine.
In 2016, Henssen et al. discuss that orofacial pain may be conducted in a bilateral fashion, inducing activation of both thalami [1]. For this reason, bilateral stimulation of the motor cortex is thought to induce a stronger analgesic effect…
Primary Objective:The primary objective is to compare the pain free rates at 15 minutes following the use of GammaCore® with that of a sham device, for acute treatment of cluster headache attacks.Secondary Objectives:The secondary objectives will…
To find a simple test to explain non-responsiveness to sumatriptan in a proportion of patients with migraine.
This study aims to investigate the sensitivity and specificity of the history and physical examination for the diagnosis of giant cell arteritis, compared with the superficial temporal artery biopsy, and get more insight into the positive and…
1. We want to study the success rate of OAHM withdrawal in patients with chronic migraine related to support by a headache nurse, and onabotulinum toxin A injections during the withdrawal period, and the influence of comorbid depression.2. We want…
to assess the single-dose safety, tolerability and pharmacokinetic profile of (6) individual doses of tonabersat ranging from 160 mg to 480 mg (or to dose-limiting toxicity (DLT)) in healthy subjects under the fasted or fed conditionsto assess the…
The objective of this study is to test the safety of the research study drug, MK-0462 (rizatriptan) and to test the ability of study drug to relieve or reduce migraine for the study population.
The primary objective in this study is to evaluate effectiveness of optimized high cervical epidural neurostimulation against placebo-stimulation in patients with intractable cervicogenic headache in a neurostimulation trial.
The purpose of the study is to investigate how safe the compound USL260 is and how well the compound USL260 is tolerated under fasting and fed conditions. The study will also investigate how quickly and to what extent the compound USL260 is absorbed…
The objective of this study is to test the safety of the research study drug, MK-0462 (rizatriptan) and to test the ability of study drug to relieve or reduce migraine for the study population.
To investigate whether probiotics can reduce incidence and severity of migraine attacks.
The primary objective is to measure R2 latencies, amplitude, duration, area and habituation of the electrically evoked *nociception specific* blink reflex before and after treatment with oxygen at a flow rate of 12 L/min during a cluster headache…
To test whether probiotics, as adjuvant therapy, can reduce incidence and severity of migraine attacks by reducing intestinal permeability.
1. Is there a decreased total peripheral resistance in supine patients with VVS after challenging them with nitroglycerine? 2. Is there a decreased total peripheral resistance in migraine after infusion of nitroglycerine? 3. What is the relation…
The primary objective of this study is to investigate whether differences in patient specific pharmacokinetic properties, both dynamic and absolute, reveal the difference in response to lithium treatment. The pharmacokinetic properties which will be…
• Test the safety of the research drug, telcagepant (MK-0974)• Test the safety of the research study drug telcagepant (MK-0974) in the prevention of menstrually related migraines. • Compare the effectiveness of the research study drug telcagepant (…
Supported by the observation from the Phase I studies in healthy volunteers, doses within a range of 50 to 500 mg are safe and well tolerated. This Phase II trial will be performed to:a. obtain proof of concept of BI 44370 TAb. perform dose finding…